{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:11:41Z","timestamp":1790727101379,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.pathol.2023.03.007","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T01:40:17Z","timestamp":1684287617000},"page":"629-636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma"],"prefix":"10.1016","volume":"55","author":[{"given":"Eva R.","family":"Shteinman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael A.","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert V.","family":"Rawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serigne N.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2090-7860","authenticated-orcid":false,"given":"Kumiko","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas Pires","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Wilmott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2023.03.007_bib1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","article-title":"Novel anticancer targets: revisiting ERBB2 and discovering ERBB3","volume":"9","author":"Baselga","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pathol.2023.03.007_bib2","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1038\/sj.onc.1206779","article-title":"Biologic and therapeutic role of HER2 in cancer","volume":"22","author":"Menard","year":"2003","journal-title":"Oncogene"},{"issue":"Suppl 2","key":"10.1016\/j.pathol.2023.03.007_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000055396","article-title":"Biology of HER2 and its importance in breast cancer","volume":"61","author":"Yarden","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.pathol.2023.03.007_bib4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.03.007_bib5","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2005.04.8397","article-title":"ErbB-3 predicts survival in ovarian cancer","volume":"24","author":"Tanner","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.03.007_bib6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/path.1370","article-title":"Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer","volume":"200","author":"Witton","year":"2003","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2023.03.007_bib7","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1158\/1078-0432.CCR-04-1158","article-title":"Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth","volume":"11","author":"Gregory","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.03.007_bib8","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1158\/1078-0432.CCR-08-1064","article-title":"High expression of HER3 is associated with a decreased survival in gastric cancer","volume":"14","author":"Hayashi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.03.007_bib9","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.bjc.6602251","article-title":"Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients","volume":"91","author":"Memon","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pathol.2023.03.007_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ccr.2006.05.024","article-title":"Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer","volume":"10","author":"Zhou","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pathol.2023.03.007_bib11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/bjc.2011.322","article-title":"Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification","volume":"105","author":"Tanizaki","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pathol.2023.03.007_bib12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.apsb.2018.05.010","article-title":"Understanding the biology of HER3 receptor as a therapeutic target in human cancer","volume":"8","author":"Lyu","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.pathol.2023.03.007_bib13","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1038\/oncsis.2014.23","article-title":"ERBB3 is required for metastasis formation of melanoma cells","volume":"3","author":"Tiwary","year":"2014","journal-title":"Oncogenesis"},{"key":"10.1016\/j.pathol.2023.03.007_bib14","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1172\/JCI65780","article-title":"Melanoma adapts to RAF\/MEK inhibitors through FOXD3-mediated upregulation of ERBB3","volume":"123","author":"Abel","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pathol.2023.03.007_bib15","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.3390\/cancers12123761","article-title":"HER3-Receptor-Mediated STAT3 activation plays a central role in adaptive resistance toward Vemurafenib in melanoma","volume":"12","author":"Huser","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pathol.2023.03.007_bib16","first-page":"355","article-title":"HER3 signaling and targeted therapy in cancer","volume":"12","author":"Mishra","year":"2018","journal-title":"Oncol Rev"},{"key":"10.1016\/j.pathol.2023.03.007_bib17","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-08-0186","article-title":"HER3 is a determinant for poor prognosis in melanoma","volume":"14","author":"Reschke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.03.007_bib18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1755-148X.2009.00616.x","article-title":"NRG1\/ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation","volume":"22","author":"Buac","year":"2009","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.pathol.2023.03.007_bib19","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/ijc.26118","article-title":"Nuclear HER3 is associated with favorable overall survival in uveal melanoma","volume":"130","author":"Trocme","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pathol.2023.03.007_bib20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1158\/1541-7786.MCR-10-0512","article-title":"Phosphoproteomic screen identifies potential therapeutic targets in melanoma","volume":"9","author":"Tworkoski","year":"2011","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.pathol.2023.03.007_bib21","article-title":"ERBB1\/2\/3 Expression, prognosis, and immune infiltration in cutaneous melanoma","volume":"12","author":"Liu","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.pathol.2023.03.007_bib22","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1200\/JCO.2021.39.15_suppl.9007","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)","volume":"39","author":"Janne","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.03.007_bib23","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2023.03.007_bib24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.03.007_bib25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2023.03.007_bib26","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: a practical approach","volume":"25","author":"Ruschoff","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.03.007_bib27","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1158\/1078-0432.CCR-15-1714","article-title":"PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage III melanoma","volume":"22","author":"Madore","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.03.007_bib28","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pathol.2023.03.007_bib29","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2023.03.007_bib30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody\u2013drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.pathol.2023.03.007_bib31","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.03.007_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials","volume":"28","author":"Madore","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.pathol.2023.03.007_bib33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2023.03.007_bib34","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.3802\/jgo.2019.30.e75","article-title":"Overexpression of HER2\/HER3 and clinical feature of ovarian cancer","volume":"30","author":"Chung","year":"2019","journal-title":"J\u00a0Gynecol Oncol"},{"key":"10.1016\/j.pathol.2023.03.007_bib35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1479-5876-9-126","article-title":"Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma","volume":"9","author":"Takikita","year":"2011","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.pathol.2023.03.007_bib36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/cgt.2008.15","article-title":"The ERBB3 receptor in cancer and cancer gene therapy","volume":"15","author":"Sithanandam","year":"2008","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.pathol.2023.03.007_bib37","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/0008-5472.CAN-10-2384","article-title":"EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment","volume":"71","author":"Liccardi","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2023.03.007_bib38","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.devcel.2014.06.008","article-title":"EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4","volume":"30","author":"Chou","year":"2014","journal-title":"Dev Cell"},{"key":"10.1016\/j.pathol.2023.03.007_bib39","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302523001216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302523001216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T13:41:08Z","timestamp":1710510068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302523001216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0031302523001216"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2023.03.007","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2023.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}